{
  "schema_version": "1.0",
  "publisher": "TirzepatideReview.com",
  "provider": "NexLife",
  "currency": "USD",
  "prices_verified_date": "2026-07-11",
  "verification_note": "Prices transcribed from NexLife's published self-pay program pages on 2026-07-11. Prices are set by NexLife and can change at any time. Always confirm the current price on the official program page before enrolling.",
  "math_rule": "monthly_equivalent = plan_total / plan_months. savings_vs_monthly = (monthly_rate * plan_months) - plan_total. Every displayed figure on this site is derived from this file.",
  "pricing_corrections_applied": [
    "Semaglutide microdose 3-month: source card showed $117/mo against a $357 total. $357 / 3 = $119. Corrected to $119/mo.",
    "Semaglutide ODT 3-month: source card showed $597 total with $185/mo and $42 savings, which cannot all be true. $185 x 3 = $555, and $199 x 3 - $555 = $42. Corrected total to $555.",
    "Tirzepatide microdose 3-month: $479 / 3 = $159.67, not $159. Displayed as approximately $160/mo.",
    "Tirzepatide microdose 6-month: $899 / 6 = $149.83, not $150. Displayed as approximately $150/mo with exact value retained."
  ],
  "program_inclusions_stated_by_nexlife": [
    "Same published program price at every covered dose",
    "No separate membership fee",
    "No hidden program fees",
    "Free expedited shipping",
    "Licensed-provider evaluation and ongoing medical oversight",
    "Coaching and patient community access"
  ],
  "regulatory": {
    "fda_status": "Compounded tirzepatide and compounded semaglutide are not FDA-approved.",
    "not_same_as_brand": "Compounded tirzepatide is not the same product as Mounjaro or Zepbound. Mounjaro and Zepbound are trademarks of Eli Lilly and Company.",
    "premarket_review": "Compounded medications do not undergo FDA premarket review for safety, effectiveness or quality.",
    "eligibility": "Prescription treatment requires evaluation and approval by a licensed healthcare provider. Availability varies by state, pharmacy and individual clinical need."
  },
  "programs": [
    {
      "id": "tirzepatide_standard",
      "medication": "tirzepatide",
      "form": "Standard injection",
      "official_url": "https://nexlife.com/pages/tirzepatide-all-plans",
      "monthly_rate": 215,
      "plans": [
        { "months": 1, "total": 215, "monthly_equivalent": 215, "monthly_display": "$215", "savings_vs_monthly": 0 },
        { "months": 3, "total": 585, "monthly_equivalent": 195.0, "monthly_display": "$195", "savings_vs_monthly": 60 },
        { "months": 6, "total": 1140, "monthly_equivalent": 190.0, "monthly_display": "$190", "savings_vs_monthly": 150 },
        { "months": 12, "total": 2232, "monthly_equivalent": 186.0, "monthly_display": "$186", "savings_vs_monthly": 348 }
      ]
    },
    {
      "id": "tirzepatide_microdose",
      "medication": "tirzepatide",
      "form": "Microdose",
      "official_url": "https://nexlife.com/pages/microdose-tirzepatide-program",
      "monthly_rate": 189,
      "plans": [
        { "months": 1, "total": 189, "monthly_equivalent": 189, "monthly_display": "$189", "savings_vs_monthly": 0 },
        { "months": 3, "total": 479, "monthly_equivalent": 159.67, "monthly_display": "~$160", "savings_vs_monthly": 88 },
        { "months": 6, "total": 899, "monthly_equivalent": 149.83, "monthly_display": "~$150", "savings_vs_monthly": 235 },
        { "months": 12, "total": 1764, "monthly_equivalent": 147.0, "monthly_display": "$147", "savings_vs_monthly": 504 }
      ]
    },
    {
      "id": "tirzepatide_odt",
      "medication": "tirzepatide",
      "form": "Oral tablet / ODT",
      "official_url": "https://nexlife.com/pages/tirzepatide-oraltablet-program",
      "monthly_rate": 229,
      "plans": [
        { "months": 1, "total": 229, "monthly_equivalent": 229, "monthly_display": "$229", "savings_vs_monthly": 0 },
        { "months": 3, "total": 657, "monthly_equivalent": 219.0, "monthly_display": "$219", "savings_vs_monthly": 30 },
        { "months": 6, "total": 1230, "monthly_equivalent": 205.0, "monthly_display": "$205", "savings_vs_monthly": 144 },
        { "months": 12, "total": 2388, "monthly_equivalent": 199.0, "monthly_display": "$199", "savings_vs_monthly": 360 }
      ]
    },
    {
      "id": "semaglutide_standard",
      "medication": "semaglutide",
      "form": "Standard injection",
      "official_url": "https://nexlife.com/pages/semaglutide-all-plans",
      "monthly_rate": 165,
      "plans": [
        { "months": 1, "total": 165, "monthly_equivalent": 165, "monthly_display": "$165", "savings_vs_monthly": 0 },
        { "months": 3, "total": 447, "monthly_equivalent": 149.0, "monthly_display": "$149", "savings_vs_monthly": 48 },
        { "months": 6, "total": 882, "monthly_equivalent": 147.0, "monthly_display": "$147", "savings_vs_monthly": 108 },
        { "months": 12, "total": 1740, "monthly_equivalent": 145.0, "monthly_display": "$145", "savings_vs_monthly": 240 }
      ]
    },
    {
      "id": "semaglutide_microdose",
      "medication": "semaglutide",
      "form": "Microdose",
      "official_url": "https://nexlife.com/pages/microdose-semaglutide-program",
      "monthly_rate": 129,
      "plans": [
        { "months": 1, "total": 129, "monthly_equivalent": 129, "monthly_display": "$129", "savings_vs_monthly": 0 },
        { "months": 3, "total": 357, "monthly_equivalent": 119.0, "monthly_display": "$119", "savings_vs_monthly": 30 },
        { "months": 6, "total": 684, "monthly_equivalent": 114.0, "monthly_display": "$114", "savings_vs_monthly": 90 },
        { "months": 12, "total": 1320, "monthly_equivalent": 110.0, "monthly_display": "$110", "savings_vs_monthly": 228 }
      ]
    },
    {
      "id": "semaglutide_odt",
      "medication": "semaglutide",
      "form": "Oral tablet / ODT",
      "official_url": "https://nexlife.com/pages/semaglutide-oraltablet-program",
      "monthly_rate": 199,
      "plans": [
        { "months": 1, "total": 199, "monthly_equivalent": 199, "monthly_display": "$199", "savings_vs_monthly": 0 },
        { "months": 3, "total": 555, "monthly_equivalent": 185.0, "monthly_display": "$185", "savings_vs_monthly": 42 },
        { "months": 6, "total": 1062, "monthly_equivalent": 177.0, "monthly_display": "$177", "savings_vs_monthly": 132 },
        { "months": 12, "total": 1980, "monthly_equivalent": 165.0, "monthly_display": "$165", "savings_vs_monthly": 408 }
      ]
    }
  ],
  "clinical_trials_fda_approved_injectable_only": [
    { "study": "SURMOUNT-1", "treatment": "Tirzepatide (FDA-approved injectable)", "dose": "5 mg", "duration_weeks": 72, "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)", "estimand": "Treatment-regimen (mean % change from baseline)", "mean_weight_change_pct": -15.0, "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216" },
    { "study": "SURMOUNT-1", "treatment": "Tirzepatide (FDA-approved injectable)", "dose": "10 mg", "duration_weeks": 72, "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)", "estimand": "Treatment-regimen (mean % change from baseline)", "mean_weight_change_pct": -19.5, "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216" },
    { "study": "SURMOUNT-1", "treatment": "Tirzepatide (FDA-approved injectable)", "dose": "15 mg", "duration_weeks": 72, "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)", "estimand": "Treatment-regimen (mean % change from baseline)", "mean_weight_change_pct": -20.9, "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216" },
    { "study": "SURMOUNT-1", "treatment": "Placebo", "dose": "n/a", "duration_weeks": 72, "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)", "estimand": "Treatment-regimen (mean % change from baseline)", "mean_weight_change_pct": -3.1, "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216" },
    { "study": "SURMOUNT-5", "treatment": "Tirzepatide (FDA-approved injectable)", "dose": "Maximum tolerated (10 or 15 mg)", "duration_weeks": 72, "population": "Adults with obesity, without type 2 diabetes; head-to-head vs semaglutide", "estimand": "Mean % change from baseline", "mean_weight_change_pct": -20.2, "source": "Aronne LJ et al. N Engl J Med. 2025 (SURMOUNT-5)" },
    { "study": "SURMOUNT-5", "treatment": "Semaglutide (FDA-approved injectable)", "dose": "Maximum tolerated (1.7 or 2.4 mg)", "duration_weeks": 72, "population": "Adults with obesity, without type 2 diabetes; head-to-head vs tirzepatide", "estimand": "Mean % change from baseline", "mean_weight_change_pct": -13.7, "source": "Aronne LJ et al. N Engl J Med. 2025 (SURMOUNT-5)" }
  ],
  "clinical_evidence_limitation": "These results come from clinical trials of FDA-approved injectable products. They do not establish the safety or effectiveness of a compounded, microdose or oral/ODT formulation. Individual results vary."
}